Docking Studies on a Series of Polo-like Kinase 4 Inhibitors

Abstract

Polo-like kinase 4 (PLK4), a mitotic kinase was regarded as a potential target for cancer therapy. a novel series of PLK4 competitive kinase inhibitors have been docked into the active site of Polo-like kinase 4 (PDB code 4JXF) by using CCDC GOLD, furthermore, the binding modes for the inhibitors generated by MOE2015 may explain the mechanism of kinase selectivity.